GMAB - genmab.com Trailing Twelve Months Revenue Growth

Brandmark of genmab.com (GMAB)

Genmab A/S (GMAB) attracts leading scientists through a Scandinavian culture of freedom and comprehensive benefits packages. A broad antibody portfolio and alliances with pharmaceutical behemoths minimize risks. The humanitarian status of its developments, which precludes sanctions, guarantees stability. This chart of LTM sales volume changes compared to last year visualizes the actual business dynamics, while 19.60 indicates the current level of this metric.

Genmab A/S - GMAB Sales Growth YoY (TTM) (period 02/11/2024 - 11/15/2026)

Genmab - analytical breakdowns and key metrics (GMAB)

- price and consensus price forecast:
Price Rate Chart Genmab US|GMAB - Analyst Consensus Forecast
- market capitalization statistics:
Market Value Genmab US|GMAB - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share Genmab|GMAB - Book Capitalization|Market-to-Book Ratio genmab.com|GMAB - Company Total Assets
- company total debt and liquidity indicators:
Debt to Equity Ratio Genmab A/S|GMAB - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Genmab US|GMAB - Company Total Debt|Debt to Book Capital Genmab A/S|GMAB - Company Long-Term Debts|Company Short-Term Loans and Borrowings Genmab|Immediate Liquidity genmab.com
- financial results and valuation multiples details:
GMAB - Company Net Income|Expected Net Income Genmab A/S|GMAB - P/E Multiple|Forward P/E Multiple genmab.com|GMAB - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Genmab US|GMAB - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Genmab|GMAB - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year genmab.com|GMAB - Earnings growth in current year|Expected net earnings per share growth next year Genmab A/S
- sales revenue and business income indicators:
GMAB - Company Revenue|Company Revenue Forecast Genmab Corp|GMAB - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple Genmab A/S|GMAB - Sales Growth YoY (TTM)
Fundamental company valuation:Genmab US GMAB
Flagship merchandise of genmab.com

Stable royalty payments from Darzalex form the cash flow foundation for Genmab A/S (GMAB), offsetting the high costs of developing new antibodies. The 12-month revenue growth trajectory reflects business scaling dynamics through a rolling sales pace, allowing investors to objectively assess operating value and the risks of demand stagnation when analyzing this metric.

Who Genmab A/S competes with

Revenue Growth Rate YoY (Last Twelve Months) Exelixis Corp|Nuvalent Inc - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Kymera|IDYA (IDEAYA Biosciences) - Revenue Growth YoY (Last 12 Months)|ELVN: Revenue Change YoY (Last 12 Months)|ORIC (oricpharma.com) - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Relay Pharma RLAY|Sales Growth YoY (TTM) NRIX|Tyra Biosciences - Sales Growth YoY (Last 12 Months)|Verastem - Revenue Growth YoY (Last 12 Months)|Revenue Dynamics YoY (Last Twelve Months) GLUE|CGEM: Revenue Growth YoY (Last 12 Months)|Immuneering Inc. - Revenue Change YoY (Last 12 Months)|CCCC: Sales Growth YoY (TTM)|Black Diamond - Revenue Dynamics YoY (Last Twelve Months)|RPTX (Repare Therapeutics Inc) - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth PMV Pharmaceuticals Inc. PMVP|Sales Growth YoY (Last Twelve Months) Karyopharm Therapeutics, Inc. (KPTI)|PPCB (Propanc Biopharma) - Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) BGMS (Cyclacel)|Sales Growth YoY (TTM) Aadi Bioscience AADI|ALRN - Sales Growth YoY (Last Twelve Months)|Trailing Twelve Months Sales Growth BPMC|GLYC (glycomimetics.com) - Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth SpringWorks Therapeutics, Inc (SWTX)